MIAMI, July 1 /PRNewswire/ -- FUISZ today announced two medical technology advances.
First, FUISZ announced that it has received a notice of issuance from the United States Patent and Trademark Office for patent claims that cover a direct connection between prescribing physicians and blood analysis devices. The invention allows for the health care provider to set the parameters of allowable analyte levels for each patient and enables simple notifications for any variance out of a pre-determined range. Joseph Fuisz, managing member of FUISZ stated, “These patent claims represents a quantum leap in the use of portable blood analyzers to provide a higher level of care for patients while reducing burdens on health care providers. We are in discussions with the blood analyzer industry for the licensing of this technology.”
FUISZ also announced that it has filed a new patent in the field of solid oral Bioactive dosage forms. This novel system works to enhance or retard drug absorption. It is particularly well suited to buccal, sublinqual and other forms of mucosal delivery including nano particles. Joseph Fuisz commented, “This innovation can be readily adapted for use with existing products to improve control of drug absorption. It will be particularly well received in the opiate market where controlling relative absorption of opiates and agonists is so critical. This technology draws upon our deep knowledge of quick dissolve dosage forms and applies that knowledge in a broad manner to all solid dosage forms.”
FUISZ is a family owned company. Fuisz principals Richard Fuisz, M.D. and Joseph Fuisz, Esq. are named inventors on or owners of hundreds of patents and patent applications. These patents span several fields: drug delivery, quick dissolve dosage forms including quick dissolve tablets, thin films, slow dissolve sheets, conventional oral dosage units, opiate abuse resistance, women’s health, electronic mail, e-commerce, and tobacco. The company is based in Miami, Florida. www.fuisz.com.
SOURCE FUISZ